CAMBRIDGE, United Kingdom, June 12, 2026
AstraZeneca has secured a major regulatory milestone with the U.S. Food and Drug Administration (FDA) approval of Truqap (capivasertib) in combination with abiraterone and prednisone for the treatment of adults with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive prostate cancer (mAPMN/S), previously known as metastatic hormone-sensitive prostate cancer. The approval makes Truqap the first and only targeted therapy specifically approved for PTEN-deficient metastatic prostate cancer, addressing a patient population associated with aggressive disease progression and poor clinical outcomes. The regulatory decision was supported by results from the pivotal Phase III CAPItello-281 trial, which demonstrated a statistically significant improvement in progression-free survival and reinforced the growing role of biomarker-driven treatment strategies in advanced prostate cancer management.
CAPItello-281 Demonstrates Significant Clinical Benefit
The FDA approval was based on findings from the global CAPItello-281 Phase III trial, which enrolled more than 1,000 patients with newly diagnosed PTEN-deficient metastatic prostate cancer. Results showed that patients receiving Truqap combined with abiraterone and androgen deprivation therapy (ADT) experienced a 19% reduction in the risk of radiographic disease progression or death compared with those receiving abiraterone and ADT alone. Median radiographic progression-free survival reached 33.2 months in the Truqap treatment arm versus 25.7 months in the control group, representing a clinically meaningful improvement of 7.5 months.
Although overall survival data remain immature, early results numerically favored the Truqap combination, suggesting potential long-term benefits for patients facing one of the most aggressive forms of prostate cancer. Investigators emphasized that PTEN deficiency occurs in approximately one in four patients diagnosed with metastatic hormone-sensitive prostate cancer and is recognized as an independent marker of poor prognosis. The positive outcomes from CAPItello-281 underscore the value of targeting the PI3K/AKT signaling pathway, a key biological driver of tumor growth in PTEN-deficient disease.
First Targeted Therapy for an Aggressive Prostate Cancer Subtype
Advertisement
PTEN loss or deficiency is one of the most common molecular alterations in advanced prostate cancer and contributes to uncontrolled tumor growth through activation of the AKT pathway. With this approval, Truqap becomes the first therapy specifically designed to address this underlying biological mechanism in metastatic hormone-sensitive disease. The FDA simultaneously approved a companion diagnostic test capable of identifying PTEN-deficient tumors, further advancing the use of precision oncology in prostate cancer care. Experts believe the approval represents an important step toward broader adoption of biomarker-guided treatment strategies that match therapies to the molecular characteristics of individual tumors.
Clinicians involved in the study highlighted that delaying disease progression remains a critical treatment goal, particularly for patients with aggressive disease biology. By targeting a key molecular driver, Truqap offers a novel therapeutic approach that may help extend remission periods and improve long-term patient outcomes.
Expanding the Clinical Impact of AKT Inhibition
The latest approval marks a significant expansion for Truqap, which previously gained regulatory approvals in breast cancer settings involving specific biomarker-defined populations. As a first-in-class AKT inhibitor, Truqap is designed to block all three AKT isoforms and disrupt cancer-promoting signaling pathways responsible for tumor survival and growth. Safety findings from CAPItello-281 were generally consistent with the known profiles of the individual therapies, with rash and hyperglycemia among the most frequently reported adverse events. AstraZeneca is also pursuing additional regulatory reviews globally, including an ongoing application in the European Union.
With prostate cancer remaining one of the most commonly diagnosed cancers in men worldwide, the approval highlights the increasing importance of molecular diagnostics, targeted therapies, and precision medicine approaches in transforming cancer treatment. The milestone further strengthens AstraZeneca’s oncology portfolio while offering new hope for patients with PTEN-deficient metastatic prostate cancer who historically faced limited targeted treatment options.
Source: AstraZeneca press release
